Recognition of cytomegalovirus clinical isolate antigens by sera from cytomegalovirus-negative blood donors

BACKGROUND:  The most common way to prevent transmission of CMV by blood transfusion is to use blood products from seronegative donors. Screening of blood donors for CMV infection is usually based on detection of antigens obtained from the CMV laboratory strain AD 169. Recent evidence suggests that...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2004-07, Vol.44 (7), p.1059-1066
Main Authors: Rahbar, A.R., Sundqvist, V.-A.S., Wirgart, B. Zweygberg, Grillner, L., Söderberg-Naucler, C.
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Antibodies, Viral - blood
Antigens, Viral - immunology
Biological and medical sciences
Blood Donors
Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis
Blotting, Western
Cytomegalovirus - immunology
Cytomegalovirus Infections - transmission
DNA, Viral - blood
Enzyme-Linked Immunosorbent Assay
Humans
Immunoglobulin G - blood
Medical sciences
Medicin och hälsovetenskap
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND:  The most common way to prevent transmission of CMV by blood transfusion is to use blood products from seronegative donors. Screening of blood donors for CMV infection is usually based on detection of antigens obtained from the CMV laboratory strain AD 169. Recent evidence suggests that approximately up to 20 percent of CMV‐negative blood donors may in fact be CMV‐DNA positive by PCR analyses. STUDY DESIGN AND METHODS:  In this study, sera from CMV‐seronegative, CMV‐seropositive, and CMV‐DNA‐positive/seronegative individuals, and from patients with acute and convalescent CMV infection for detection of CMV antibodies were analyzed. CMV antigens pre‐pared from cells infected with CMV clinical isolates or the CMV laboratory strain AD 169 in ELISA and Western blot assays were used. RESULTS:  All CMV‐positive sera from blood donors were seropositive for the CMV antigens prepared from AD 169 (A2) or from a CMV clinical isolate (C6). Interestingly, whereas all CMV‐negative blood donors were negative in tests for the CMV antigen A2, 36 percent were CMV seropositive using the CMV antigen C6 in ELISA. CONCLUSION:  The data suggest that a substantial number of CMV‐seronegative/CMV‐DNA‐positive serum samples contain antibodies that recognize CMV clinical isolate antigens.
ISSN:0041-1132
1537-2995
DOI:10.1111/j.1537-2995.2004.03292.x